Cargando…

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection

Acquisition of non-sterilizing natural immunity to Plasmodium falciparum malaria has been shown in low transmission areas following multiple exposures. However, conflicting data from endemic areas suggest that the parasite may interfere with the induction of effective B-cell responses. To date, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elias, Sean C, Choudhary, Prateek, de Cassan, Simone C, Biswas, Sumi, Collins, Katharine A, Halstead, Fenella D, Bliss, Carly M, Ewer, Katie J, Hodgson, Susanne H, Duncan, Christopher J A, Hill, Adrian V S, Draper, Simon J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Ltd 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956436/ https://www.ncbi.nlm.nih.gov/pubmed/24303947 http://dx.doi.org/10.1111/imm.12226

Ejemplares similares

Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure
por: Biswas, Sumi, et al.
Publicado: (2014)

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors
por: Sheehy, Susanne H., et al.
Publicado: (2012)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
por: Afolabi, Muhammed O, et al.
Publicado: (2016)

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS
por: de Barra, Eoghan, et al.
Publicado: (2014)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals
por: Hodgson, Susanne H., et al.
Publicado: (2015)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
por: Tiono, Alfred B., et al.
Publicado: (2018)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
por: Mensah, Victorine A., et al.
Publicado: (2016)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
por: de Graaf, Hans, et al.
Publicado: (2021)

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
por: Rampling, Tommy, et al.
Publicado: (2018)

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
por: O’Hara, Geraldine A., et al.
Publicado: (2012)

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults
por: Ogwang, Caroline, et al.
Publicado: (2013)

A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP
por: Bauza, Karolis, et al.
Publicado: (2012)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
por: Morter, Richard, et al.
Publicado: (2022)

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan
por: Younis, Brima M., et al.
Publicado: (2021)

Cohort study of the association of antibody levels to AMA1, MSP1(19), MSP3 and GLURP with protection from clinical malaria in Ghanaian children
por: Dodoo, Daniel, et al.
Publicado: (2008)

Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial
por: Hodgson, Susanne H, et al.
Publicado: (2014)

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients: A multicenter prospective observational study
por: Haase, Michael, et al.
Publicado: (2022)

Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
por: Ewer, Katie J., et al.
Publicado: (2013)

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
por: Osman, Mohamed, et al.
Publicado: (2017)

Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909
por: Duncan, Christopher J. A., et al.
Publicado: (2011)

The influence of intestinal parasites on Plasmodium vivax-specific antibody responses to MSP-1(19) and AMA-1 in rural populations of the Brazilian Amazon
por: Sánchez-Arcila, Juan Camilo, et al.
Publicado: (2015)

Genetic diversity in two leading Plasmodium vivax malaria vaccine candidates AMA1 and MSP1(19) at three sites in India
por: Kale, Sonal, et al.
Publicado: (2021)

Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1()
por: Douglas, Alexander D., et al.
Publicado: (2010)

Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria
por: Peng, Heng, et al.
Publicado: (2010)

Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults
por: Hu, Jinhong, et al.
Publicado: (2008)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice()
por: Ondondo, Beatrice, et al.
Publicado: (2013)

Speakers AMA
por: CERN. Geneva
Publicado: (2019)

Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites
por: Bauza, Karolis, et al.
Publicado: (2014)

LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis
por: Lacey, Charles, et al.
Publicado: (2022)

Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1
por: Biswas, Sumi, et al.
Publicado: (2011)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
por: Ahmed, T, et al.
Publicado: (2012)

Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs
por: Finch, Courtney L., et al.
Publicado: (2022)

Genetic diversity and the ensuing strain specific immunity to asexual erythrocytic stage vaccine candidate antigens, MSP-1, AMA-1 and DBP, of Plasmodium vivax in Sri Lanka
por: Udagama-Randeniya, Preethi, et al.
Publicado: (2010)

The AMA Handbook of Leadership
por: Goldsmith, Marshall, et al.
Publicado: (2010)

MSP For Dummies
por: Ferguson, Alan
Publicado: (2014)

Chad : development potential and constraints /
Publicado: (1974)

MSP430 microcontroller basics
por: Davies, J H
Publicado: (2008)

Clinical Variation of Plasmodium falciparum eba-175, ama-1, and msp-3 Genotypes in Young Children Living in a Seasonally High Malaria Transmission Setting in Burkina Faso
por: Soulama, Issiaka, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j7d1eb5lusu8u141s6fe69ppcp